Compounded semaglutide is considered an eligible medical expense when prescribed by a licensed provider for a diagnosed medical condition (obesity or type 2 diabetes)
The buyer assumes full responsibility for safe handling, storage, and lawful use in accordance with all applicable regulations
Participants were randomized to receive placebo or one of several retatrutide dose levels (1 mg, 4 mg, 8 mg, or 12 mg) administered subcutaneously once weekly for 48 weeks
To increase the stability of GLP-1R, the fusion protein rubredoxin was inserted into intracellular loop 2 (ICL2) of GLP-1R between positions 257 to 262 and 11 mutations were introduced
The original formulation required twice-daily injections, though an extended-release version allows weekly dosing
Always consult a qualified healthcare professional before making changes to your medication, diet, or exercise regimen.